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Formalin-killed, purified Rickettsia rickettsii vaccine was evaluated in a guinea
pig model of R. rickettsii infection. Vaccinated guinea pigs were partially
protected by the vaccine when challenged with virulent, viable rickettsiae.
Greater protection was observed when higher doses of vaccine were given and
when frequent booster injections were administered. Stimulation of cell-mediated
immunity to the vaccine antigens was variable and also appeared to be achieved
more reproducibly with booster vaccinations. Serum antibody was elicited by
high doses of vaccine and by booster vaccinations. The presence of serum
antibody was useful in predicting immunity to challenge with R. rickettsii.
Rocky Mountain spotted fever (RMSF) is an
acute febrile illness caused by Rickettsia rickett-
sii. The disease has a significant mortality rate
and is a disease for which a vaccine is needed to
protect individuals living in endemic areas. The
vaccines which were available previously have
not reliably prevented infection by R. rickettsii
(2, 13). Previous vaccines consisted of killed R.
rickettsii harvested either from infected ticks
(13) or from embryonated hen eggs (2). Both
vaccines contained nonrickettsial antigens of
eggs or whole macerated ticks and offered in-
complete protection against disease.
The purpose of this investigation was to evalu-
ate a Formalin-inactivated R. rickettsii vaccine
Sheila Smith strain (SS strain), chick embryo
cell culture origin (freeze-dried lot no. 1), sup-
plied by the United States Army Medical Re-
search Institute of Infectious Diseases (USAM-
RIID), Frederick, Md. (5) in a guinea pig model.
Infection of guinea pigs with R. rickettsii gives a
characteristic course of febrile illness and death
(6). The vaccine was administered intradermal-
ly, subcutaneously or intramuscularly. Animals
were challenged at various times after vaccina-
tion by injection with virulent R. rickettsii. Daily
rectal temperatures were recorded, and blood
was taken from survivors for antibody determi-
nations and lymphocyte transformation studies.
MATERIALS AND METHODS
Determination of optimal route of vaccination. Forty-
eight adult male Hartley guinea pigs (weight, >500 g)
were bled three days before vaccination to obtain 1- to
2-ml prevaccination serum samples. All animals were
ear-tagged for identification purposes. On day 0, 12
guinea pigs were vaccinated by intradermal, subcuta-
neous, or intramuscular route of injection. Six animals
were inoculated by each route and received 0.5 ml of a
1:3 dilution of vaccine. The other six animals received
0.5 ml of a 1:100 dilution. Vaccine was a Formalin-
inactivated SS strain, chicken embryo cell culture
origin, freeze-dried, lot no. 1, as supplied by USAM-
RIID. Twelve animals in the control group were
injected intramuscularly with 0.5 ml of saline. On day
10 postvaccination, a sample of four animals was bled
for lymphocyte transformation. This was repeated on
days 21 and 30 postvaccination. Postvaccination anti-
body titers were assayed by indirect immunofluores-
cence with serum collected on day 28. On day 30, all
animals were challenged intraperitoneally with 1.0 ml
of blood-spleen suspension from R. rickettsii-infected
guinea pigs. The infectious dose of the blood-spleen
suspension was quantified and standardized in terms
of tissue culture median infectious dose as determined
by immunofluorescent demonstration of R. rickettsii.
A challenge dose of 2 x 102 of tissue culture median
infectious dose per ml was prepared by dilution in
sucrose phosphate glutamate before injection. Daily
rectal temperatures were recorded starting on day 5
after infectious challenge and continuing for a week.
The duration of fever and the percentage of animals
with fever were recorded. Blood samples for lympho-
cyte transformation were taken from survivors on
days 12, 20, and 27 after inoculation. Convalescent
antibody titers were determined by indirect immuno-
fluorescence on serum taken on day 27 postchallenge.
Evaluation of long-term protection. Male Hartley
strain guinea pigs (250) were vaccinated with Formal-
in-inactivated SS strain chicken embryo cell culture
origin vaccine provided by USAMRIID. All animals in
the long-term study were vaccinated subcutaneously.
This study was initiated first because of the duration of
the study, and animals were vaccinated subcutaneous-
ly on the basis that this was the route previously used
for all three RMSF vaccines in humans. (See Table 4
for the schedule used.)
On day 396 after the first vaccination, four or five
animals from each group were challenged intraperito-
neally with 1.0 ml of a 1:50 dilution of a guinea pig
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blood-spleen suspension containing 2 x 102 tissue
culture median infectious doses of virulent R. rickett-
sii. Challenged guinea pigs were examined for fever
starting on day 5 postinoculation and continuing
through day 12. Whole blood samples were taken from
survivors on day 14 postinoculation for lymphocyte
transformation tests. Serum samples were collected 28
days after challenge and tested by indirect immunoflu-
orescence for convalescent antibody titers. Ten of the
survivors were then sacrificed, and the spleens were
removed aseptically for lymphocyte transformation
tests. The remaining animals were challenged 1.5 and 2
years after initial vaccination.
Determination of optimal dose of vaccine and require-
ments for booster vaccination. Adult male guinea pigs
(64) were bled for prevaccination sera and divided into
groups of 8 to 12 animals which were vaccinated with a
vaccine dose of a 1:3, 1:20, or 1:100 dilution. One-half
of the animals were given booster vaccinations of the
same dose 30 days after the first vaccination and one-
half received no booster vaccination. Ten control
animals were given saline as a sham vaccine and were
challenged by the same procedure as the vaccinated
animals.
One-half of the guinea pigs were challenged by
inoculation of R. rickettsii intraperitoneally; the other
half were challenged by intradermal inoculation. After
challenge with virulent R. rickettsii on day 30 after the
last dose of vaccine, animals were observed for mor-
bidity and mortality, and daily rectal temperatures
were recorded on days 4 to 12 after rickettsial chal-
lenge. All survivors were bled on day 28 postchallenge
to examine for antibody to R. rickettsii by indirect
immunofluorescence assay.
Lymphocyte transformation. Blast transformation
studies were performed with guinea pig lymphocytes
obtained from the peripheral blood or spleen from
vaccinated animals. The methods were previously
described by Pavia et al. (11). Phytohemagglutinin was
used for mitogenic stimulation, and Formalin-killed
rickettsiae (FRR) were used as a specific stimulant.
Stimulation indices of greater than 10 were considered
significant for mitogen responses, and indices of 3 or
greater were considered significant for responses to
FRR (8).
Serological studies. Antibody to R. rickettsii was
measured by indirect immunofluorescence with rick-
ettsiae fixed to slides and a fluorescein-labeled rabbit
anti-guinea pig serum (12). Detection of antibodies at a
1:16 titer was considered a significant antibody re-
sponse. A Leitz-Ortholux UV microscope with inci-
dent beam illumination was used with barrier and
exciter filters for fluorescein.
RESULTS
Effect of intramuscular injection of RMSF vac-
cine. The results from a group of experiments in
which RMSF vaccine was given intramuscularly
are given in Table 1. The animals were chal-
lenged 30 days after intramuscular administra-
tion of the vaccine with virulent rickettsiae. In
the group of guinea pigs that received the higher
dose of vaccine (1:3 dilution), all animals devel-
oped antibody titers of -1:16 by 28 days, and all
animals survived challenge with virulent orga-
nisms. Blood was taken from two animals of the
group, and lymphocytes were cultured in vitro
with mitogen and FRR. The animals responded
to mitogen but gave poor responses to rickettsial
antigens. Animals receiving a lower dose of
vaccine (1:100) failed to develop detectable anti-
bodies by 28 days after administration of the
vaccine, except for one guinea pig which devel-
oped an antibody titer of 1:16. However, all
animals survived, and there was no suppression
of lymphocyte transformation by mitogen.
Effect of subcutaneous injection of RMSF vac-
cine. Studies on guinea pigs vaccinated by the
subcutaneous route demonstrated that with the
higher dose of vaccine (1:3) two of six animals
developed fever upon challenge with virulent
organisms but all survived (Table 2). Two of the
vaccinated animals produced significant anti-
body titers by day 28 after vaccination, and five
of six guinea pigs had detectable antibody re-
sponses by 28 days after challenge. Lymphocyte
transformation studies indicated that repre-
sentative animals of the group responded to
mitogens, and one animal responded to FRR in
vitro. Only one guinea pig vaccinated with a
1:100 dilution of vaccine had antibody detected
at a titer of 1:16 28 days after vaccination, but
five of six animals had significant antibody lev-
els at 28 days after challenge. Three of six
animals developed fever upon challenge, but all
guinea pigs survived. Lymphocytes from guinea
pigs of this group responded in vitro to mitogens
but not to FRR under the conditions used in
these experiments.
Effect of intradermal injection of RMSF vac-
cine. All guinea pigs receiving a 1:3 dilution of
TABLE 1. Effect of intramuscular injection of RMSF vaccine into guinea pigsa
Microimmunofluorescence antibody titer Outcome of challenge as Lymphocyte
range(GMT):
Outcome ofchallenge as transformation
Group Vaccine ge ( no. of animals febrile/ (stimulation index) for:
no. dose no. of animals
Day 28 Day 28 inoculated PHA FRR
postvaccination postinfection
I 1:3 1:16-1:256 (1:102) 1:128-1:512 (1:256) 0/6 39, 51 1.2, 3.1
II 1:100 Neg-1:16 (1:9) 1:16-1:2,048 (1:81) 1/5 15, 60 2.3, 2.5
a Abbreviations: PHA, phytohemagglutinin stimulation; FRR, Formalin-killed R. rickettsii antigenic stimula-
tion; GMT, geometric mean titer of <1:16 assigned an arbitrary value of 1:8, Neg, <1:16 antibody titer.
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TABLE 2. Effect of subcutaneous injection of RMSF vaccine into guinea pigsa
Microimmunofluorescence antibody titer range Outcome of challenge Lymphocyte
(GMT)at:
Outcome of challenge as transformation
Group Vaccine (GT) at: no. of animals febrile/ (stimulation index) for:
no. dose no. of animals
Day 28 Day 28 inoculated PHA FRR
postvaccination postinfection
I 1:3 Neg-1:512 (1:37) Neg->1:2,048 (1:372) 2/6 35, 98 2.1, 3.4
II 1:100 Neg-1:16 (1:9) Neg-1:2,048 (1:311) 3/6 33, 66 2.3, 2.6
a Abbreviations: GMT, geometric mean titer of <1:16 assigned an arbitrary value of 1:8; PHA, phytohemag-
glutinin stimulation; FRR, Formalin-killed R. rickettsii antigenic stimulation; Neg, <1:16 antibody titer.
RMSF vaccine intradermally survived challenge
with R. rickettsii at 30 days after vaccination
(Table 3). Five of six guinea pigs had significant
postvaccination antibody titers before chal-
lenge. One animal failed to make detectable
antibody even after challenge. In this experi-
ment, the animal without detectable antibody
(<1:16) failed to develop fever and survived.
Two guinea pigs receiving the 1:100 dilution of
vaccine also failed to show detectable antibody
before challenge; however, one of those animals
did produce antibody after challenge. Three of
five animals developed fever, and one animal
died 11 days after challenge without detectable
antibody. It also should be noted that one guinea
pig which failed to make detectable antibody
survived without developing fever. Results of in
vitro lymphocyte transformation indicated that
responses to mitogens were within the usual
range, i.e., >10, but no response to rickettsial
antigen was detected.
Controls for vaccination experiments. Twelve
guinea pigs served as controls for the vaccine
studies. All controls were given sterile pyrogen-
free saline on day 1, were bled 28 days later, and
were challenged with virulent organisms on day
30. None of these guinea pigs had detectable
antibody before challenge. However, five ani-
mals had significant levels 28 days after chal-
lenge. Seven of the 12 animals developed fever,
and two animals died from the infection. It is
interesting that one animal never developed a
fever yet did synthesize antibodies (titer of
1:2,048) after challenge. In addition, two ani-
mals developed neither fever nor detectable
antibodies and survived the infection. None of
the animals studied responded to rickettsial anti-
gens in vitro, but they did respond to mitogens.
Effect of long-term vaccination with RMSF
vaccine. Data on 10 groups of guinea pigs with
different vaccination schedules over 366 days
are given in Table 4. All animals were injected
subcutaneously with a low dose of vaccine
(1:100), a high dose of vaccine (1:3), or saline.
All animals were challenged at 13 months, 1.5
years, and 2 years after the initial injection.
Animals in groups VII and VIII (Table 4) that
received three doses of either a 1:3 or 1:100
dilution of vaccine all survived challenge at 13
months, and only one animal developed a fever.
In contrast, animals receiving two doses of
vaccine (Table 4, groups V and VI) differed in
protection from disease according to vaccine
dose. Three of four animals receiving a 1:3 dose
of vaccine survived challenge at 13 months and
made antibody. Lymphocytes from these sur-
viving animals responded strongly to rickettsial
antigens and mitogens in vitro. Animals which
received two vaccinations with a 1:100 dose (on
days 1 and 366) all developed fever upon chal-
lenge and four of five animals died. There was a
poor in vitro lymphoblastic response to FRR in
the sole survivor in group VI (Table 4). The
results of challenge after 1.5 and 2 years were
generally similar to those at 13 months. Among
the nonvaccinated controls, 16 of 20 animals
developed fever, and 14 of the 16 febrile animals
died.
TABLE 3. Effect of intradermal injection of RMSF vaccine into guinea pigsa
Microimmunofluorescence antibody titer range Outcomeofchalenge as Lymphocyte
I(GMT)at: Outcom of challenge as transformationGroup Vaccine (M)a:no. of animals febrile/ (stimulation index) for:
no. dose no. of animals
Day 28 Day 28 inoculated PHA FRR
postvaccination postinfection
I 1:3 Neg-1:2,048 (1:100) Neg-1:1,024 (1:252) 0/6 26, 48 2.3, 2.8
II 1:100 Neg-1:16 (1:9) Neg-1:1,024 (1:81) 3/5b 49, 85 1.3, 2.2
a Abbreviations: GMT, geometric mean titer of <1:16 assigned an arbitrary value of 1:8; PHA, phytohemag-
glutinin stimulation; FRR, Formalin-killed R. rickettsii antigenic stimulation; Neg, <1:16 antibody titer.
b Outcome of challenge was death for one animal.
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TABLE 4. Effect of long-term vaccination of guinea pigs with RMSF vaccine
Response at 13 mo as Response at 1.5 yr as Response at 2 yr asVaccination Vaccine no. of animals no. of animals no. of animals
Group no. schedule dose febrile/no. of animals febrile/no. of animals febrile/no. of
(days) inoculateda inoculateda animals inoculated0
I 1 1:3 2/4 (1) 0/5 313b
II 1 1:100 4/5 (4) 4/4 (4) 3/5 (3)
III 1, 30 1:3 1/5 (1) 0/5 1/4
IV 1, 30 1:100 4/5 (2) 5/5 (4) 4/5 (3)
V 1, 366 1:3 1/4 (1) 0/5 1/4 (1)
VI 1, 366 1:100 5/5 (4) 3/3 (1) 4/4 (4)
VII 1, 30, 366 1:3 0/4 (0) 1/4 0/2
VIII 1, 30, 366 1:100 1/4 (0) 3/5 (2) 0/4
IX and X None Saline 7/8 (5) 5/6 (5) 4/6 (4)
a Number of animals with fatal courses are given in parentheses.
b All three animals were febrile for only 1 day.
Determination of optimal dose and requirement
for booster vaccination. The results of various
doses and booster regimens of vaccine are pre-
sented in Table 5. All doses of vaccine were
given subcutaneously. The highest dose of vac-
cine was most effective, and the lowest dose was
least effective. The effects of booster vaccina-
tion were apparent at vaccine dilutions of 1:20
and 1:100, at which dilutions fewer booster-
vaccinated animals developed a fever after chal-
lenge.
Determination of immunity parameters which
are predictors of protection. Animals that were
vaccinated once with vaccine dilutions of 1:3,
1:20, or 1:100 and were challenged 30 days later
showed some correlation between postvaccina-
tion antibody response and protection from dis-
ease due to R. rickettsii (Table 6). Twelve of 33
(36%) animals vaccinated once and with anti-
body titers of <1:16 became febrile. Only 1 of 14
(7%) animals vaccinated once and with antibody
titers of -1:64 became febrile, and 10 of 11
unvaccinated animals, which were, of course,
seronegative, became febrile on challenge.
Animals that were vaccinated twice 30 days
apart with dilutions of vaccine of 1:3, 1:20, or
1:100 and that were challenged 30 days after the
booster vaccination showed a correlation of
antibody titer with response to challenge with R.
rickettsii. One of three animals (33%) with an
antibody titer of <1:16 developed a fever after
challenge. Two of nine animals (22%) with an
antibody titer of 1:128 developed a fever after
challenge. None of 20 animals (0%) with an
antibody titer of .1:256 became febrile.
Cell-mediated immunity as measured by lym-
phocyte transformation on exposure to FRR was
not highly correlated with protection on chal-
lenge. One animal with a postvaccination stimu-
lation index of less than 2 remained afebrile
upon challenge. Two of four guinea pigs with
postvaccination stimulation indices in the range
of 2 to 3 became febrile after challenge. One of
the two guinea pigs with a significant postvac-
cination stimulation index, more than 3, never-
theless developed a fever after challenge.
DISCUSSION
It is apparent from these studies that vaccina-
tion of guinea pigs with the higher dose (1:3) of
vaccine is protective against challenge with via-
ble R. rickettsii under certain conditions. First, a
single dose is partially protective if given within
30 days before challenge with virulent orga-
nisms. The frequency of vaccination is some-
what less important for long-term protection
since it appears that animals receiving three
doses of vaccine over 366 days were not more
resistant to challenge with virulent R. rickettsii
than were animals that received high-dose vac-
cine at 1 and 30 days and at 1 and 366 days.
Lower doses (1:100) of vaccine did not seem to
provide protection against challenge, except in
experiments when vaccine was administered
three times over a year. In this situation, most of
the animals remained afebrile upon challenge
and none of the animals died. Determination of
TABLE 5. Determination of optimal dose and
requirement for booster
Group no. Vaccine dose' Boostere challengec
XI 1:3 No 0/8
XII 1:3 Yes 0/11
XIII 1:20 No 3/12
XIV 1:20 Yes 1/10
XV 1:100 No 7/12 (1)
XVI 1:100 Yes 2/11
XVII Saline No 9/10 (7)
a Vaccine was given by subcutaneous route.
b Booster of same dose given on day 30 after first
inoculation.
c Outcome of challenge given as the number of
febrile animals per the total number of animals inocu-
lated. Numnber of deaths is given in parentheses.
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TABLE 6. Correlation of prechallenge antibody titer
and response to challenge with R. rickettsii
Postvaccination Outcome of challenge afterb:




a Reciprocal titer of indirect immunofluorescent
antibody to R. rickettsii.
b Outcome of challenge given as the number of
febrile animals per the total number of animals chal-
lenged.
the relationship between the dose of vaccine
which affords protection to guinea pigs and the
vaccine dose which affords similar protection to
humans remains problematical. If the mass of
protective vaccine were related to the mass of
the recipient, then a 70-kg man would require
much more vaccine than a 500-g guinea pig. In
initial human studies of the vaccine, 0.5-ml
doses of the 1:3 dilution were administered (1).
This dose contained 0.37 mg of protein. Since
this was the dose which we demonstrated as
protecting guinea pigs, it is conceivable that a
larger dose might be required to confer protec-
tion to humans. Moreover, the requirement for
booster vaccinations to maintain long-term pro-
tection from infection is a severe drawback for
the achievement of immune protection for a
relatively large population at risk.
In contrast to studies by Kenyon et al. (3), a
small portion of the animals used in this study
did develop lymphocyte transformation respons-
es to rickettsial antigens after vaccination. It
should be pointed out, however, that Kenyon et
al. (3) were using whole blood lymphocyte cul-
tures instead of enriched lymphocyte popula-
tions, and their cultures were established in
guinea pig serum which may contain nonspecific
inhibitors of lymphocyte transformation (9). The
vaccinated animals also developed specific anti-
body to R. rickettsii. The higher dose of vaccine
was effective in eliciting a higher titer of anti-
body, and the level of antibody was a reliable
predictor of protection. Several negative obser-
vations were made, and they warrant further
discussion. There was no evidence of suppres-
sion of lymphocyte transformation to mitogens
by vaccination nor was suppression of lympho-
cyte transformation to mitogens observed after
challenge of these animals. This is in contrast to
the report of Oster et al. (10) who reported a
transient depression of lymphocyte responses
within a few days after infection with R. rickett-
sii. It is possible that we did not observe the
decreased lymphocyte responses because we
were studying lymphocyte transformation 28
days after challenge, and the depressed respons-
es noted by Oster et al. (10) were seen in the first
10 days after infection. No immunopathological
sequelae of vaccination or postvaccination chal-
lenge were observed in these experiments, and
no systemic toxicity of the vaccine was noted.
These studies also indicate that the guinea pig
model of infection is an acceptable one. Our
results on guinea pig mortality are similar to
those of Kenyon et al. (4) in that approximately
one-half of the infected, nonvaccinated control
animals died during infection. Most of these
animals developed fever within 5 days after
inoculation. This apparently low mortality rate
may be a result of the utilization of outbred
guinea pigs in which individual, nonspecific
resistance may have been a factor.
There is a definite need for a vaccine against
RMSF, particularly in certain geographical re-
gions and in patients with occupational or genet-
ic risk factors. The mortality rate for RMSF in
North Carolina in 1980 (7) was equal to the
mortality rate for poliomyelitis in the United
States in 1956 (14) (0.3 deaths per 100,000 popu-
lation). The development of an effective vaccine
for this obligate, intracellular bacterium requires
more basic knowledge about the antigens of R.
rickettsii and the components of the immune
system which must be stimulated to confer im-
mune protection against this disease. Acquisi-
tion of these data should be pursued.
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